Meridian Bioscience stock plummets on worsened outlook
Diagnostic testing company Meridian Bioscience (Nasdaq: VIVO) saw its shares fall as much as 13 percent in early trading Thursday, as the company downwardly revised its full-year earnings outlook. Shares of Meridian, whose tests can help doctors detect c. diff infection symptoms, were hovering around $23.87 in late-morning trading, after closing at $27.32 the prior […]